Ocuphire Pharma Investor Presentation Deck
Disclosures and Forward-Looking Statements
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but
are not limited to, statements concerning the success and timing of planned regulatory filings and approvals, pre-commercial activities, commercialization
strategy and timelines, business strategy, product labels, cash runway, scalability, future clinical trials in presbyopia (P), dim light/night vision disturbance
(DLD) and diabetic retinopathy (DR) / diabetic macular edema (DME), including the potential for Nyxol to be a "best in class" presbyopia drop, and timing of
planned future clinical trials for APX3330, APX2009 and APX2014, timing and occurrence of an End-of-Phase 2 meeting with the FDA, the potential of a Phase 3
registration path for APX3330, the success and timing of planned regulatory filings, business strategy, cash runway, scalability, the potential for APX3330 to be the
most advanced and the first line of therapy for DR patients, and the potential market opportunity for the slowing of DR progression. These forward-looking
statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results
and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including,
without limitation: (i) the success, costs, and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii)
regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks
related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi)
legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) risks that the partnership with Viatris may not facilitate
the commercialization or market acceptance of Ocuphire's product candidates; (ix) the success and timing of commercialization of any of Ocuphire's product
candidates, including the scalability of Ocuphire's product candidates and (x) the maintenance of Ocuphire's intellectual property rights. The foregoing review of
important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with
statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by the Company from time
to time with the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained in or incorporated
by reference into this presentation. Nothing contained in or incorporated by reference into this presentation is, or shall be relied upon as, a promise or
representation by the Company as to the past or future. The Company assumes no responsibility for the accuracy or completeness of any such information.
This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our
industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The trademarks included
herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.
Ocuphire
2View entire presentation